Exagen Inc. (E08A)
XFRA 
Summary
E08A Chart
How Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05%
The average of price targets set by Wall Street analysts indicates a potential upside of 73.1% in Exagen (XGN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Exagen Inc. (XGN) Q1 2026 Earnings Call Transcript
Exagen Inc. (XGN) Q1 2026 Earnings Call Transcript
Exagen Q1 Earnings Call Highlights
Exagen NASDAQ: XGN reported record first-quarter revenue and reaffirmed its full-year outlook, as executives said growth in testing volume, improved reimbursement execution and expanding clinician adoption helped offset a weather-related disruption early in the quarter.
Exagen Inc. (E08A) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Exagen Inc. ever had a stock split?
Exagen Inc. Profile
| Professional Services Industry | Industrials Sector | John Aballi CEO | XFRA Exchange | 30068X103 CUSIP |
| US Country | 216 Employees | - Last Dividend | - Last Split | 19 Sep 2019 IPO Date |
Overview
Exagen Inc. is an innovative healthcare company specializing in the development and commercialization of testing products aimed at improving the care of patients with autoimmune and autoimmune-related diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company’s portfolio is built around its proprietary cell-bound complement activation products technology, marketed under the AVISE brand within the United States. Its mission encompasses assisting rheumatologists in diagnosing, prognosting, and monitoring diseases, ultimately enhancing patient care. Initially known as Exagen Diagnostics, Inc., the company rebranded to Exagen Inc. in January 2019. Founded in 2002, Exagen Inc. is headquartered in Vista, California, and sustains a strong research partnership with Allegheny Health Network (AHN) Research Institute for the development of novel patented biomarkers.
Products and Services
- AVISE CTD: Offers differential diagnosis for patients displaying symptoms of various connective tissue diseases (CTDs) and other diseases with overlapping symptoms.
- AVISE Lupus: A diagnostic tool that quantifies the level of B-cell C4d and erythrocyte bound C4d, measuring the activation of the complement system in lupus patients.
- AVISE APS: Comprises a panel of autoantibody tests aiding in the diagnosis and management of Antiphospholipid Syndrome (APS).
- AVISE SLE Prognostic: Utilizes a panel of autoantibodies to assess the potential for complications in SLE patients affecting the kidney, brain, and cardiovascular system.
- AVISE Vasculitis AAV: A diagnostic panel for the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis, providing detailed results with individual analytes.
- AVISE Anti-CarP: Identifies RA patients at a higher risk of severe disease through the detection of specific autoantibodies.
- AVISE PC4d: Measures platelet-bound C4d, offering important insights for specific autoimmune conditions.
- AVISE SLE Monitor: A biomarker blood test for the monitoring of disease activity in SLE patients.
- AVISE MTX: A patented and validated blood test to monitor methotrexate polyglutamates, assisting in the management of patients on methotrexate therapy.
- AVISE HCQ: Provides monitoring of hydroxychloroquine levels in the blood, ensuring therapeutic efficacy and safety in patients undergoing treatment.
